Hepatitis B risk factors
Hepatitis B risk factors On the Web
American Roentgen Ray Society Images of Hepatitis B risk factors
Common risk factors in the development of HBV infection include sexual contact with infected individuals, sharing a household with a carrier, intravenous drug use, travel to endemic regions, perinatal transmission from infected mothers to infants, and certain occupations.
- Infants born to infected mothers
- Young children in day-care or residential settings with other children in endemic areas
- Sexual/household contacts of infected persons
- Patients and employees in hemodialysis centers
- Injection drug users sharing unsterilized needles
- People sharing unsterilized medical or dental equipment
- People providing or receiving acupuncture and/or tattooing with unsterilized medical devices
- Persons living in regions or travelling to regions with endemic hepatitis B
- Country of origin is the major risk factor for HBV infection (prevalence threshold of 2% or greater to define countries with high risk for HBV infection)
- Sexually active heterosexuals
- Lack of vaccination in infancy
- Men who have sex with men
- Hemophilia patients
- Travel to areas where hepatitis B is common
Hepatitis B Reactivation
Hepatitis B virus presents in all patients with infection. Patients who are either HBsAg-positive or anti HBc-positive are at the risk of hepatitis B reactivation.
- Receive immunosuppressive therapy
- Patients treated with direct-acting antivirals for hepatitis C
- Viekira Pak/ Viekira Pak XR
- World Health Organization. Department of Cummunicable Disease Surveillance and Response http://apps.who.int/iris/bitstream/10665/67746/1/WHO_CDS_CSR_LYO_2002.2_HEPATITIS_B.pdf
- US. Preventive Services Task Force. Screening for Hepatitis B infection. (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-b-virus-infection-screening-2014?ds=1&s=hepatitis%20b Accessed on October 4th, 2016
- "Hepatitis B" (PDF).
- Lee YH, Bae SC, Song GG (2013). "Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.". Clin Exp Rheumatol. 31 (1): 118–21. PMID 23111095.
- Kim PS, Ho GY, Prete PE, Furst DE (2012). "Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.". Arthritis Care Res (Hoboken). 64 (8): 1265–8. PMID 22392695. doi:10.1002/acr.21654.
- Sagnelli E, Manzillo G, Maio G, Pasquale G, Felaco FM, Filippini P; et al. (1980). "Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis.". Lancet. 2 (8191): 395–7. PMID 6105519.
- Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C (1985). "Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis.". Liver. 5 (1): 8–12. PMID 3884951.
- Europian Medicines Agency. reviews direct-acting antivirals for hepatitis C. (2016) http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Direct-acting_antivirals_for_hepatitis_C_20/Procedure_started/WC500203479.pdf
- U.S Food and Drug Adminestration. Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C http://www.fda.gov/downloads/Drugs/DrugSafety/UCM523499.pdf